S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
Log in

NASDAQ:BIIBBiogen News Headlines

$281.27
+4.75 (+1.72 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$274.14
Now: $281.27▼
$281.76
50-Day Range
$258.66
MA: $281.47▼
$307.09
52-Week Range
$215.77
Now: $281.27▼
$374.99
Volume895,745 shs
Average Volume1.92 million shs
Market Capitalization$45.90 billion
P/E Ratio8.68
Dividend YieldN/A
Beta0.54

Headlines

Biogen (NASDAQ BIIB) News Headlines

Source:
DateHeadline
Eisai and Biogen launch Phase 3 BAN2401 program in asymptomatic alzheimers diseaseEisai and Biogen launch Phase 3 BAN2401 program in asymptomatic alzheimer's disease
seekingalpha.com - July 14 at 3:04 PM
Biogen, Eisai Start New Phase 3 Trial For Pre-clinical Alzheimer’s DiseaseBiogen, Eisai Start New Phase 3 Trial For Pre-clinical Alzheimer’s Disease
finance.yahoo.com - July 14 at 3:04 PM
Could The Market Be Wrong About Biogen Inc. (NASDAQ:BIIB) Given Its Attractive Financial Prospects?Could The Market Be Wrong About Biogen Inc. (NASDAQ:BIIB) Given Its Attractive Financial Prospects?
finance.yahoo.com - July 14 at 3:04 PM
Initiation Of New Phase III Clinical Study (AHEAD 3-45) Of BAN2401 Preclinical (Asymptomatic) Alzheimer's DiseaseInitiation Of New Phase III Clinical Study (AHEAD 3-45) Of BAN2401 Preclinical (Asymptomatic) Alzheimer's Disease
finance.yahoo.com - July 13 at 10:59 PM
Goldman Sachs Group Lowers Biogen (NASDAQ:BIIB) Price Target to $257.00Goldman Sachs Group Lowers Biogen (NASDAQ:BIIB) Price Target to $257.00
www.marketbeat.com - July 13 at 7:34 AM
Biogen (NASDAQ:BIIB) PT Lowered to $257.00Biogen (NASDAQ:BIIB) PT Lowered to $257.00
www.americanbankingnews.com - July 13 at 7:30 AM
Biogen: Approval Prospects for Aducanumab Amount to a Flip of a Coin, Says J.P. Morgan - Yahoo FinanceBiogen: Approval Prospects for Aducanumab Amount to a Flip of a Coin, Says J.P. Morgan - Yahoo Finance
finance.yahoo.com - July 11 at 12:31 AM
Biogen: Approval Prospects for Aducanumab Amount to a Flip of a Coin, Says J.P. MorganBiogen: Approval Prospects for Aducanumab Amount to a Flip of a Coin, Says J.P. Morgan
finance.yahoo.com - July 11 at 12:31 AM
Biogen (NASDAQ:BIIB) Receives Hold Rating from William BlairBiogen (NASDAQ:BIIB) Receives Hold Rating from William Blair
www.marketbeat.com - July 10 at 12:19 PM
The Petri Dish: $890M in new deals and an Alzheimers drug application - Boston Business JournalThe Petri Dish: $890M in new deals and an Alzheimer's drug application - Boston Business Journal
www.bizjournals.com - July 9 at 11:55 PM
Biogen Files FDA Application For Potential Alzheimer Treatment - Yahoo FinanceBiogen Files FDA Application For Potential Alzheimer Treatment - Yahoo Finance
finance.yahoo.com - July 9 at 6:54 PM
Biogen Files BLA for Alzheimer's Drug Aducanumab, Stock UpBiogen Files BLA for Alzheimer's Drug Aducanumab, Stock Up
finance.yahoo.com - July 9 at 1:54 PM
Biogens (BIIB) Buy Rating Reiterated at SunTrust BanksBiogen's (BIIB) Buy Rating Reiterated at SunTrust Banks
www.americanbankingnews.com - July 9 at 10:08 AM
Biogen Files FDA Application For Potential Alzheimer TreatmentBiogen Files FDA Application For Potential Alzheimer Treatment
finance.yahoo.com - July 9 at 8:50 AM
Is Biogen Stock A Buy Now That Its Alzheimer's Drug Is In FDA's Court?Is Biogen Stock A Buy Now That Its Alzheimer's Drug Is In FDA's Court?
finance.yahoo.com - July 9 at 8:50 AM
Biogen (NASDAQ:BIIB) Given Buy Rating at GuggenheimBiogen (NASDAQ:BIIB) Given Buy Rating at Guggenheim
www.americanbankingnews.com - July 9 at 7:27 AM
Biogens stock rises on submission to FDA for Alzheimers drug application - MarketWatchBiogen's stock rises on submission to FDA for Alzheimer's drug application - MarketWatch
www.marketwatch.com - July 9 at 12:15 AM
Biogen Stock Jumps After Alzheimer’s Drug Submitted for FDA Approval - BarronsBiogen Stock Jumps After Alzheimer’s Drug Submitted for FDA Approval - Barron's
www.barrons.com - July 9 at 12:15 AM
Stock Alert: Biogen Up 5%; Submits Application To FDA For Aducanumab - NasdaqStock Alert: Biogen Up 5%; Submits Application To FDA For Aducanumab - Nasdaq
www.nasdaq.com - July 8 at 7:12 PM
Biogen moves forward with potential Alzheimers drug, seeks U.S. approval - ReutersBiogen moves forward with potential Alzheimer's drug, seeks U.S. approval - Reuters
www.reuters.com - July 8 at 2:12 PM
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers Disease - GlobeNewswireBiogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease - GlobeNewswire
www.globenewswire.com - July 8 at 2:12 PM
Traders Buy High Volume of Call Options on Biogen (NASDAQ:BIIB)Traders Buy High Volume of Call Options on Biogen (NASDAQ:BIIB)
www.americanbankingnews.com - July 8 at 11:25 AM
Biogen Inc.: Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers DiseaseBiogen Inc.: Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease
www.finanznachrichten.de - July 8 at 9:09 AM
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s DiseaseBiogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease
finance.yahoo.com - July 8 at 9:09 AM
Biogen completes U.S. application for Alzheimers drug aducanumabBiogen completes U.S. application for Alzheimer's drug aducanumab
seekingalpha.com - July 8 at 9:09 AM
Dow Jones Today, Futures Rise As China, Gold Rally; A Walmart+ Subscription Service? Biogen Alzheimer's LicenseDow Jones Today, Futures Rise As China, Gold Rally; A Walmart+ Subscription Service? Biogen Alzheimer's License
finance.yahoo.com - July 8 at 9:09 AM
US STOCKS-Wall St set to gain on rebound hopes despite jump in virus casesUS STOCKS-Wall St set to gain on rebound hopes despite jump in virus cases
finance.yahoo.com - July 8 at 9:09 AM
Biogen's stock rises on submission to FDA for Alzheimer's drug applicationBiogen's stock rises on submission to FDA for Alzheimer's drug application
finance.yahoo.com - July 8 at 9:09 AM
Biogens (BIIB) Hold Rating Reaffirmed at Royal Bank of CanadaBiogen's (BIIB) Hold Rating Reaffirmed at Royal Bank of Canada
www.americanbankingnews.com - July 6 at 12:08 PM
Why Biogen Shares Fell 12.9% in June - Motley FoolWhy Biogen Shares Fell 12.9% in June - Motley Fool
www.fool.com - July 2 at 6:20 PM
Why Biogen Shares Fell 12.9% in JuneWhy Biogen Shares Fell 12.9% in June
finance.yahoo.com - July 2 at 6:20 PM
Forget Vertex, Biogen Is a Better Value Stock - Motley FoolForget Vertex, Biogen Is a Better Value Stock - Motley Fool
www.fool.com - July 1 at 9:22 AM
Biogen Inc. (BIIB): Were Hedge Funds Right About This Stock? - Yahoo FinanceBiogen Inc. (BIIB): Were Hedge Funds Right About This Stock? - Yahoo Finance
finance.yahoo.com - June 29 at 2:34 PM
Biogen and Southwest Are on the Casualty List - Yahoo FinanceBiogen and Southwest Are on the Casualty List - Yahoo Finance
finance.yahoo.com - June 29 at 2:34 PM
Biogen Inc. (BIIB): Were Hedge Funds Right About This Stock?Biogen Inc. (BIIB): Were Hedge Funds Right About This Stock?
finance.yahoo.com - June 29 at 2:34 PM
Is This Bargain Biotech Stock a Treasure or a Trap? - Motley FoolIs This Bargain Biotech Stock a Treasure or a Trap? - Motley Fool
www.fool.com - June 27 at 9:09 AM
Biogen Inc (NASDAQ:BIIB) Expected to Post Quarterly Sales of $3.43 BillionBiogen Inc (NASDAQ:BIIB) Expected to Post Quarterly Sales of $3.43 Billion
www.americanbankingnews.com - June 27 at 2:40 AM
IN BRIEF: No rehearing for Biogen in Tecfidera patent appeal – Fed. Circuit - ReutersIN BRIEF: No rehearing for Biogen in Tecfidera patent appeal – Fed. Circuit - Reuters
www.reuters.com - June 26 at 12:19 AM
Brokerages Expect Biogen Inc (NASDAQ:BIIB) to Announce $7.96 Earnings Per Share Brokerages Expect Biogen Inc (NASDAQ:BIIB) to Announce $7.96 Earnings Per Share
www.americanbankingnews.com - June 25 at 3:18 PM
Biogens (BIIB) "Hold" Rating Reaffirmed at Credit Suisse GroupBiogen's (BIIB) "Hold" Rating Reaffirmed at Credit Suisse Group
www.americanbankingnews.com - June 25 at 1:01 PM
Biogen comes up empty in effort to block Tecfidera competitor - Seeking AlphaBiogen comes up empty in effort to block Tecfidera competitor - Seeking Alpha
seekingalpha.com - June 25 at 9:15 AM
Biogens Statistical Gymnastics And PR Maneuvering Will Likely Turn Aducanumab Straw Into Mega Blockbuster Gold - Seeking AlphaBiogen's Statistical Gymnastics And PR Maneuvering Will Likely Turn Aducanumab Straw Into Mega Blockbuster Gold - Seeking Alpha
seekingalpha.com - June 25 at 12:08 AM
Biogen comes up empty in effort to block Tecfidera generic competitor - Seeking AlphaBiogen comes up empty in effort to block Tecfidera generic competitor - Seeking Alpha
seekingalpha.com - June 24 at 2:07 PM
Biogen Inc. (BIIB) Management Presents at SVB Leerinks CybeRx Series: 2nd Annual CNS Forum Conference (Transcript) - Seeking AlphaBiogen Inc. (BIIB) Management Presents at SVB Leerink's CybeRx Series: 2nd Annual CNS Forum Conference (Transcript) - Seeking Alpha
seekingalpha.com - June 24 at 3:41 AM
Why the Coming Year Will Make or Break Biogens Stock - Motley FoolWhy the Coming Year Will Make or Break Biogen's Stock - Motley Fool
www.fool.com - June 23 at 5:39 PM
Biogen Inc (NASDAQ:BIIB) Given Consensus Recommendation of "Hold" by AnalystsBiogen Inc (NASDAQ:BIIB) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - June 23 at 2:42 PM
Why the Coming Year Will Make or Break Biogens Stock - NasdaqWhy the Coming Year Will Make or Break Biogen's Stock - Nasdaq
www.nasdaq.com - June 23 at 12:39 PM
Biogen Stock Falls After Another Bull Moves to the Sidelines on Patent Worries - BarronsBiogen Stock Falls After Another Bull Moves to the Sidelines on Patent Worries - Barron's
www.barrons.com - June 22 at 8:18 PM
Biogen Stock Is Falling After a Bull Moves to the Sidelines Over Patent WorriesBiogen Stock Is Falling After a Bull Moves to the Sidelines Over Patent Worries
finance.yahoo.com - June 22 at 3:17 PM
Biogen Stock Off After Barclays Downgrade on Patent RulingBiogen Stock Off After Barclays Downgrade on Patent Ruling
finance.yahoo.com - June 22 at 3:17 PM
This page was last updated on 7/14/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.